Dyne Therapeutics(US:DYN) Prnewswireยท2025-06-24 07:43Core Viewpoint - DJS Law Group is investigating Dyne Therapeutics for potential violations of securities laws following a significant drop in share price after the company announced revised trial protocols [1][2]. Investigation Details - The investigation centers on whether Dyne Therapeutics made misleading statements or failed to disclose critical information to investors [2]. - Following a June 17, 2025 announcement regarding feedback from the FDA and new efficacy data, Dyne's shares fell by over 19.4% during intraday trading on the same day [2]. Company Background - DJS Law Group specializes in enhancing investor returns through legal advocacy, focusing on securities class actions, corporate governance litigation, and M&A appraisals [4].